Vertex's ion channel inhibitor receives Phase 2 clinical proof of concept

Vertex Pharmaceuticals today announced positive results from two Phase 2 proof-of-concept clinical trials of its investigational selective NaV1.

VX-548 is an oral selective inhibitor of NaV1.

In a Phase 2 clinical trial in abdominoplasty patients, VX-548 met the primary endpoint, with a statistically significant increase in pain score SPID48 in patients treated with high doses of VX-548 compared to placebo

Image source: Reference [1]

In a phase 2 clinical trial for the treatment of bunionectomy surgery, high-dose VX-548 achieved similar efficacy, significantly improving patients' SPID48 scores

Image source: Reference [1]

In terms of safety, VX-548 was well tolerated and there were no serious adverse events associated with VX-548

References:

[1] Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain.